Related Experiment Video
Updated: Feb 21, 2026
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Immunization with α-synuclein/Grp94 reshapes peripheral immunity and suppresses microgliosis in a chronic
Javier Villadiego1,2,3, Adahir Labrador-Garrido4,5, Jaime M Franco4,5
1Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocio-CSIC-Universidad de Sevilla, Seville, Spain.
Abstract:
Neuroinflammation mediated by chronically activated microglia, largely caused by abnormal accumulation of misfolded α-synuclein (αSyn) protein, is known to contribute to the pathophysiology of Parkinson's disease (PD). In this work, based on the immunomodulatory activities displayed by particular heat-shock proteins (HSPs), we tested a novel vaccination strategy that used a combination of αSyn and Grp94 (HSPC4 or Gp96) chaperone and a murine PD model. We used two different procedures, first, the adoptive transfer of splenocytes from αSyn/Grp94-immunized mice to recipient animals, and second, direct immunization with αSyn/Grp94, to study the effects in a chronic mouse MPTP-model of parkinsonism. We found that both approaches promoted a distinct profile in the peripheral system-supported by humoral and cellular immunity-consisting of a Th1-shifted αSyn-specific response accompanied by an immune-regulatory/Th2-skewed general phenotype. Remarkably, this mixed profile sustained by αSyn/Grp94 immunization led to strong suppression of microglial activation in the substantia nigra and striatum, pointing to a newly described positive effect of anti-αSyn Th1-responses in the context of PD. This strategy is the first to target αSyn and report the suppression of PD-associated microgliosis. Overall, we show that the αSyn/Grp94 combination supports a distinct and long-lasting immune profile in the peripheral system, which has an impact at the CNS level by suppressing chronic microglial activation in an MPTP model of PD. Furthermore, our study demonstrates that reshaping peripheral immunity by vaccination with appropriate misfolding protein/HSP combinations could be highly beneficial as a treatment for neurodegenerative misfolding diseases.
Insights
This study developed a novel vaccination using alpha-synuclein (αSyn) and Grp94 to reduce neuroinflammation in Parkinson's disease (PD). The approach suppressed microglial activation, offering a potential new treatment for PD and other neurodegenerative diseases.
Area of Science:
- Neuroimmunology
- Neurodegenerative Diseases
- Vaccine Development
Background:
- Chronic microglial activation, driven by misfolded alpha-synuclein (αSyn), is central to Parkinson's disease (PD) pathophysiology.
- Heat-shock proteins (HSPs) possess immunomodulatory properties relevant for therapeutic intervention.
Purpose of the Study:
- To investigate a novel vaccination strategy combining αSyn and Grp94 (HSPC4/Gp96) chaperone for Parkinson's disease (PD).
- To evaluate the impact of this combined immunization on neuroinflammation and microglial activation in a mouse model of PD.
Main Methods:
- Utilized two immunization procedures: adoptive transfer of splenocytes and direct immunization with αSyn/Grp94 in a chronic MPTP mouse model of parkinsonism.
- Assessed peripheral immune responses (humoral and cellular immunity) and central nervous system (CNS) effects, specifically microglial activation in the substantia nigra and striatum.
Main Results:
- The αSyn/Grp94 immunization induced a distinct peripheral immune profile: a Th1-shifted αSyn-specific response alongside a general immune-regulatory/Th2-skewed phenotype.
- This mixed immune profile significantly suppressed microglial activation in the substantia nigra and striatum.
- Demonstrated a novel beneficial effect of anti-αSyn Th1 responses in suppressing PD-associated microgliosis.
Conclusions:
- The αSyn/Grp94 combination vaccination elicits a unique, sustained peripheral immune response with significant impact on CNS neuroinflammation in an MPTP-induced PD model.
- This strategy represents the first approach targeting αSyn to suppress PD-associated microgliosis.
- Reshaping peripheral immunity through vaccination with specific misfolded protein/HSP combinations holds promise for treating neurodegenerative diseases.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:37Neural Regulation